Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MAMH - New Breast Cancer detection method -- Ignore unavailable to you. Want to Upgrade?

To: DuGen who wrote (808)	11/12/1998 10:20:00 AM
From: Gary West	Read Replies (1) \| Respond to of 971

All we need is one, decent PR and the stock will rise like John Holmes on a good night. An earlier PR this year caused the stock to rise to low 20's and could happen again, with a little luck. GW P.S. I send E-mail to the company requesting answers to some questions (info@mammacare.com) and will hopefully share the response soon.

To: DuGen who wrote (808)	11/12/1998 10:52:00 AM
From: Gary West	Read Replies (1) \| Respond to of 971

So we can all be hopeful about the future, this previous PR should help. MAMMATECH CORP (BB:MAMH) files SEC Form 10-Q EDGAR Online, Thursday, July 09, 1998 at 16:55 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATION FOR MAMMATECH CORPORATION The third quarter of Fiscal 1998 was a substantial improvement over the previous quarter and over the third quarter from a one year ago. Sales were up 201% over the previous quarter and were 82.4% greater than sales during the third quarter of 1997. Operating income of $29,354 reflects an increase of 183% from the previous year and compares favorably with the $42,276 loss experienced during the previous quarter.The net income for the current quarter was 2750% above the $453 reported for the previous quarter. The nine month figures show a 44% increase in sales for the current year but a 14% decline in operating income. Comparisons among other nine-month figures from a year ago are affected by the fact that the Company is now administering a Phase II SBIR grant that added to both its operating expense and net income for the period. Thus, for example, the nine-month figure for net income for this year is 156% greater than the corresponding figure for last similarly, operating expense increased by 68% compared with a year ago whereas cost of sales increased by only 29.9%. During the quarter,the Company extended its relationship with its German distributor by training 3 health care professionals (two physicians and one nurse) as MammaCare Specialists. This will provide the basis for extensive outreach to the medical community in Germany which will, the Company hopes, help solidify acceptance of the MammaCare technology among the women of that country. The Company also trained six additional specialists, including a physician from a major medical school who will be introducing the MammaCare method of clinical breast examination to resident training in that institution. The Company also made a substantial sale of breast models and other training materials to the American Medical Women's Association for their use in training U.S. military personnel and their dependents. Many of these are follow-up orders from similar sales made last year. The Company made a major sale of specially constructed breast models to the California Department of Health. That organization is actively disseminating a program of clinical breast examination training using the Company's products and procedures.There can be no assurance, however, that any of these customers will continue to procure materials at the present rate or that substantial revenues will accrue to the Company as a result of their involvement. Finally, the Company introduced two new products during the quarter. It has added dark-skinned models to the Home Practice Series in response to numerous requests, particularly from American Cancer Society units. It also added a new evaluation lamp which projects the MammaCare grid on the torso of the patient being trained or examined. This grid provides a basis for precise measurement of the examination performance, a hallmark of the MammaCare procedure since its days in the laboratory. The Company remains essentially debt-free and has no immediate liquidity problems. It continues to pursue a corporate affiliation designed to help it realize the full commercial potential of its products. To view the full document, go to: MAMMATECH CORP 10-Q For other Edgar reports on MAMMATECH CORP (MAMH), go to: List of Edgar-Online reports for MAMH